Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Aprea Therapeutics Closes EUR 50 Million Financing
Venture Capital

Aprea Therapeutics Closes EUR 50 Million Financing

by posted 10months ago 44 views
BOSTON and STOCKHOLM, November 30, 2018-- Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the closing of a EUR 50 million Series C financing round led by the Redmile Group, with participation by new investor Rock Springs Capital and existing investors 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB (Nasdaq Stockholm: KDEV). A representative from Redmile Group will also be appointed as Director to the Aprea Therapeutics Board of Directors.